INFIQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
INFIQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Infinity Pharmaceuticals's Change In Payables And Accrued Expense for the quarter that ended in Jun. 2023 was $0.77 Mil. It means Infinity Pharmaceuticals's Accounts Payable & Accrued Expense increased by $0.77 Mil from Mar. 2023 to Jun. 2023 .
Infinity Pharmaceuticals's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2022 was $-0.30 Mil. It means Infinity Pharmaceuticals's Accounts Payable & Accrued Expense declined by $0.30 Mil from Dec. 2021 to Dec. 2022 .
The historical data trend for Infinity Pharmaceuticals's Change In Payables And Accrued Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Infinity Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Change In Payables And Accrued Expense | Get a 7-Day Free Trial | 2.83 | 1.55 | 0.88 | 2.18 | -0.30 |
Infinity Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
Change In Payables And Accrued Expense | Get a 7-Day Free Trial | 0.81 | -0.03 | -0.88 | -2.23 | 0.77 |
Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.
Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.37 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Infinity Pharmaceuticals's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.
Adelene Q Perkins | director, officer: President & CEO | C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Stephane Peluso | officer: Chief Scientific Officer | 1100 MASSACHUSETTS AVENUE, CAMBRIDGE MA 02138 |
Brian Schwartz | director | C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803 |
Robert Jr. Ilaria | officer: Chief Medical Officer | 1100 MASSACHUSETTS AVENUE, 4TH FLOOR, CAMBRIDGE MA 02138 |
Biotechnology Value Fund L P | other: See Explanation of Responses | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Bvf Gp Holdings Llc | 10 percent owner | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
Bvf Ii Gp Llc | other: See Explanation of Responses | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
Bvf I Gp Llc | other: See Explanation of Responses | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
Richard Gaynor | director | C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139 |
Jeffery Kutok | officer: Chief Scientific Officer | 784 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Samuel Agresta | officer: Chief Medical Officer | 784 MEMORIAL DR., CAMBRIDGE MA 02139 |
David W Beier | director | AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799 |
Lawrence E Bloch | officer: EVP, CFO & CBO | |
Michael Kauffman | director | C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459 |
Michael C Venuti | director |
From GuruFocus
By Marketwired • 10-11-2023
By PRNewswire • 08-26-2023
By PRNewswire • 09-02-2023
By PRNewswire • 09-16-2023
By PRNewswire • 08-27-2023
By PRNewswire • 08-28-2023
By Marketwired • 09-10-2023
By Marketwired • 09-28-2023
By ACCESSWIRE • 09-11-2023
By GuruFocus Research • 09-14-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.